Cart
Orders
Not available hereProduct Overview
B-colamin Inj. is a hydroxocobalamin injectable medicine from Daehan Nupharm, documented as a prescription product in the manufacturer's Korean brochure. Each 2 mL ampoule contains 5 mg of hydroxocobalamin, and the manufacturer lists a 50-ampoule pack. Also documented as Bicolamin Inj., this product is presented here for professional specification comparison. Buyers should confirm the supplied carton, current labeling and destination-market requirements before procurement.
Key Features
- Defined active ingredient: Hydroxocobalamin is the active ingredient identified in the manufacturer's product documentation.
- Ampoule strength: Each 2 mL ampoule contains 5 mg of hydroxocobalamin.
- Manufacturer-listed packaging: 50 ampoules per pack.
- Prescription classification: The Korean manufacturer brochure identifies Bicolamin Inj. as a prescription medicine; this does not establish authorization or purchase eligibility in other markets.
Composition & Specifications
| Specification | Details |
|---|---|
| Product name | B-colamin Inj. |
| Alternative documented name | Bicolamin Inj. |
| Manufacturer | Daehan Nupharm Co., Ltd. |
| Product category | Injectable medicine; prescription classification in Korean manufacturer documentation |
| Active ingredient | Hydroxocobalamin |
| Strength | 5 mg/2 mL; 5 mg per ampoule |
| Ampoule volume | 2 mL |
| Manufacturer-listed pack | 50 ampoules |
The ingredient entry identifies the principal active ingredient, not a complete excipient declaration. Confirm the actual sale-unit label and packaging before procurement.
Frequently Asked Questions
Does 5 mg/2 mL describe the ampoule or the entire pack?
The strength applies to one ampoule: each 2 mL ampoule contains 5 mg of hydroxocobalamin. The manufacturer-listed pack contains 50 ampoules.
Why are both B-colamin Inj. and Bicolamin Inj. used?
Both English names appear in Daehan Nupharm documentation for the hydroxocobalamin 5 mg/2 mL product. Match the active ingredient, strength and packaging rather than relying on the spelling alone.
Does Korean prescription classification establish availability in another country?
No. The Korean classification does not establish destination-market authorization, import permission or purchaser eligibility. These requirements must be checked for the intended market.